Zhejiang Huakang Pharmaceutical Co., Ltd. Class A

Zhejiang Huakang Pharmaceutical Co., Ltd. Class A

SSSE:605077
9.86
CNY
-0.02
(-0.20%)
0.34EPS
37.53P/E
3.49BMarket Cap
Apr 22Next Earn
Zhejiang Huakang Pharmaceutical Co., Ltd. Class A
SSE:605077
(Shanghai Stock Exchange)

Recent

price

9.86

P/E

ratio

37.53

div

yld

4.43%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.97
4.87
6.53
6.78
8.29
5.54
7.42
9.36
9.41
13.8
16.14
Revenue per Share
0.15
0.29
0.93
1.21
1.93
0.82
1.08
1.25
0.9
0.66
0.31
Basic EPS, GAAP
0.35
0.34
0.09
0.67
0.52
-0.34
-0.9
-0.24
-4.3
-0.19
- -
Free Cash Flow per Basic Share
0.12
0.12
0.22
0.24
0.38
0.42
0.38
0.58
0.66
0.84
0.44
Dividend per Share
0.71
0.98
1.98
3.07
4.22
8.2
8.94
10.13
10.6
10.69
10.58
Book Value per Share
0.53
0.83
1.84
2.82
3.97
7.81
8.04
8.07
8.47
8.57
8.48
Tangible Book Value per Share
193
190
214
223
159
288
296
297
298
303
305
Basic Weighted Avg Shares
763
925
1,400
1,511
1,320
1,594
2,200
2,783
2,808
4,189
4,925
Sales/Revenue/Turnover
6.82
9.09
15.6
19.62
26.21
13.24
13.97
15.29
10.57
7.72
5.5
Operating Margin (%)
45
45
49
52
60
85
106
173
201
292
- -
Depreciation Expense
29
56
199
270
307
237
319
371
268
200
94
Net Income, GAAP
15.19
12.74
11.24
12.32
11.86
6.83
6.86
11.84
6.2
10.26
- -
Effective Tax Rate (%)
3.76
6.05
14.24
17.88
23.28
14.85
14.51
13.35
9.56
4.78
1.9
Profit Margin (%)
-217
-164
-10
158
219
1,347
1,369
2,393
902
983
959
Working Capital
5
4
47
27
53
21
346
1,868
1,863
2,117
2,279
LT Debt
136
188
441
685
940
2,434
2,656
3,101
3,255
3,255
3,208
Total Equity
- -
12.81
33.75
33.86
31.56
12.94
11.06
8.62
4.97
3.46
- -
Return on Invested Capital (%)
- -
16.42
36.97
35.67
32.08
13.04
11.27
9.25
5.5
4.86
- -
Return on Capital (%)
- -
34.57
63.42
47.99
37.82
14.03
12.54
12.93
8.48
6.18
2.91
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,207
1,288
1,446
LT Borrowings
2,052
2,134
2,266
LT Finance Leases
8
12
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
303
303
303
Market Capitalization
4,512
3,276
3,490

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,478
3,243
3,716
Cash, Cash Equivalents & STI
1,124
1,049
1,640
Accounts Receivable, Net
638
723
682
Inventories
917
814
883
Total Current Liabilities
2,509
2,388
2,757
Payables & Accruals
- -
- -
- -
ST Debt
1,207
1,288
1,446
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
37.98%
-0.02%
Free Cash Flow
- -
298.51%
-95.4%
Net Income, GAAP
- -
-4.97%
-25.4%
Sales/Revenue/Turnover
- -
27.07%
49.15%
Total Cash Common Dividend
- -
37.6%
28.95%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
635
724
747
703
2,808
2025
817
1,049
- -
1,230
4,189
2026
1,187
1,294
1,214
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.27
0.2
0.17
0.27
0.9
2025
0.27
0.18
- -
0.11
0.66
2026
0.07
0.07
0.07
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.58
0.03
0.02
0.66
2025
0.03
0.55
- -
0.04
0.84
2026
0.03
0.34
0.03
- -
- -
Business
Zhejiang Huakang Pharmaceutical Co., Ltd. (605077.SS) engages in the research, development, production and sale of functional polyols, starch sugars, rare sugars and dietary fiber worldwide, serving industries including confectionery, beverages, baking, dairy, personal care, pharmaceuticals and nutraceuticals. Founded in 1962 and headquartered at 18 Huagong Road, Huabu Town, Kaihua County, Quzhou, Zhejiang Province, China, the company operates as a national high-tech enterprise with subsidiaries such as Henan Jiaozuo Huakang Sugar Alcohol Technology Co., Ltd., Zhejiang Huakang Enterprises Co., Ltd., Zhejiang Huakang Pharma B.V. and Anhui Huayue Food Technology Co., Ltd., supporting an integrated raw material supply, production and sales system across China and global markets. Its core polyols portfolio includes xylitol for confectionery, baking, beverages and pharma; sorbitol for confectionery, seafood and personal care; maltitol for chocolate and baking; erythritol for beverages and nutraceuticals; lactitol for sugar-free candies and ice cream; mannitol for chewing gum and pharma; and isomalt for oral care and supplements; while starch sugars encompass high fructose syrup, glucose syrup, maltose syrup and maltodextrin for beverages, dairy and bakery; rare sugars feature D-xylose for pet food and flavors, L-arabinose for diabetic foods; and dietary fiber includes polydextrose for frozen foods and supplements. In recent developments, the company announced in October 2024 its intent to acquire 100% equity in Yusweet Co., Ltd. (also referred to as Yuxin Sugar Alcohol) for approximately CNY 1.098 billion through a mix of share issuance and cash, targeting enhanced xylitol production capacity and industry leadership; it also progresses a corn deep-processing project in Zhoushan and advances R&D collaborations, including a 2025 study on xylitol's gut microbiota benefits published with Zhejiang Gongshang University and COFCO.